Dr Andrii Domanskyi – a neurobiologist with over 18 years of experience gained in both academia and the pharmaceutical industry – will present his research on chronic pain and neurodegenerative disease modeling during a seminar on April 16 at 14:00 in the Main Hall of Łukasiewicz – PORT.
A scientist from Orion Pharma (Finland) will introduce an approach that integrates multiple levels of analysis – from cellular studies, through functional assessments, to brain imaging techniques. He will discuss cell-based models using sensory neurons that enable the investigation of how inflammatory factors influence neuronal activity. The application of advanced measurement methods allows for precise tracking of changes in neuronal activity and the identification of potential therapeutic targets.
These studies are complemented by functional analyses supported by machine learning–based tools, enabling a more objective and precise assessment of pain-related processes that are often difficult to capture using traditional methods.
An important part of the presentation will also cover brain imaging techniques, which make it possible to link observed changes with the activity of the nervous system. This approach plays a significant role in translating research findings into clinical practice. The integration of these methods allows for a better understanding of the complex mechanisms of pain and supports the development of more effective and precise therapies.
The seminar is open to all those interested in chronic pain research, particularly early-career researchers and PhD candidates.
About the Speaker
Dr. Andrii Domanskyi focuses on the use of in vitro and ex vivo models to investigate the mechanisms of neurodegenerative diseases and chronic pain.
After obtaining his PhD from the University of Helsinki, he spent seven years at the German Cancer Research Center (DKFZ, Heidelberg), where he contributed to the development of novel models of neurodegenerative diseases.
Upon returning to Finland, his research centered on the therapeutic potential of neural stem cells in neurodegeneration. At the Institute of Biotechnology, University of Helsinki, he established his own research group, developing experimental models and systems for drug screening.
Currently at Orion Pharma (Finland), Dr. Domanskyi designs and oversees preclinical studies on novel analgesic therapies and leads research projects.
